75 cutánea 30-45 minutos antes de la inducción, o intravenosa 10-15 minutos antes, especialmente si se utilizarán opioides emetógenos. Su efecto clínico se extiende hasta 24 horas tras una dosis única.15 Conclusión La integración de maropitant en los protocolos anestésicos representa un avance significativo en la anestesia veterinaria moderna: apoyo analgésico (según evidencias), previene náuseas y vómitos, y contribuye a una recuperación más rápida y confortable. Su perfil de seguridad y versatilidad lo convierten en un importante coadyuvante dentro del enfoque de analgesia multimodal. Autora: Mariana Corneglian C Machado M.Sc. en Veterinaria y Product Manager en Alivira LA INTEGRACIÓN DE MAROPITANT EN LOS PROTOCOLOS ANESTÉSICOS REPRESENTA UN AVANCE SIGNIFICATIVO EN LA ANESTESIA VETERINARIA MODERNA Referencias 1. Côté, E. et al. Ettinger’s Textbook of Veterinary Internal Medicine, 9th ed., 2024. 2. Nelson, W. R., Couto, C. G. Medicina interna de pequeños animals, 6ª ed., 2020. 3. Fossum, T. W. et al. Small Animal Surgery, 5th ed., 2019. 4. Pang, D. S. J. Anesthetic and Analgesic Adjunctive Drugs. IN: Kurt, A. G. et al. Veterinary Anesthesia and Analgesia, The Fifth Edition of Lumb and Jones, 2015, 248. 5. Brittany, M. A. et al. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Veterinary Anaesthesia and Analgesia, 2012, 39, 201–205. 6. Kinobe, R. T., Miyake Y. Evaluating the anti-inflammatory and analgesic properties of maropitant: A systematic review and meta-analysis. The Veterinary Journal, 2020, 259–260. 7. Niyom, S. et al. Effect of maropitant, a neurokinin-1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats. Veterinary Anaesthesia and Analgesia, 2013. 8. Okano, K. et al. Dose- dependent isoflurane-sparing effect of maropitant in dogs undergoing ovariohysterectomy. Journal of Animal and Veterinary Advances, 2015, 14, 95-99. 9. Kraus, B. L. H. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Veterinary Anaesthesia and Analgesia, 2013, 40, 28–34. 10. Corrêa, J. M. X. et al. Evaluation of the Antinociceptive Effect of Maropitant, a Neurokinin-1 Receptor Antagonist, in Cats Undergoing Ovariohysterectomy. Veterinary Medicine International, 2019. 11. Soares, P. C. L. R. et al. Continuous Infusion of Ketamine and Lidocaine Either with or without Maropitant as an Adjuvant Agent for Analgesia in Female Dogs Undergoing Mastectomy. Veterinary Medicine International, 2021. 12. Bozkurt, G. et al. Does maropitant provide more effective perioperative pain management than meloxicam in bitches undergoing ovariohysterectomy? The first report on the comparison of visceral algesia-analgesia for ovariohysterectomy. Research in Veterinary Science, 2024, 169. 13. Boscan, P. et al. Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs. AJVR, 2011, 72, 12, 1576-1579 14. Karna, S.R. et al. Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. New Zealand Veterinary Journal, 2021. 15. Benchaoui, H. A. et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J. vet. Pharmacol. Therap., 2007, 30, 336–344.
RkJQdWJsaXNoZXIy NTI5ODA=